Innate immunity of hematological disorders

Innate immunity of hematological disorders - Innate immunity of hematological disorders

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000003305

Enrollment

200

Registered

2010-03-10

Start date

2010-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute leukemia, chronic leukemia, malignant lymphoma, multiple myeloma, myelodysplastic syndrome, myeloproliferative disorders, immune thrombocytopenia, autoimmune hemolytic anemia, patients after hematopoietic stem cell transplantation

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Subjects with following disorders, who accepted to sign informed consent, acute leukemia, chronic leukemia, malignant lymphoma, multiple myeloma, myelodysplastic syndrome, myeloproliferative disorders, immune thrombocytopenia, autoimmune hemolytic anemia, after hematopoietic stem cell transplantation. healthy volunteers

Exclusion criteria

Exclusion criteria: Subjects who cannot understand the informed consent. Subjects whom chief physician judge on unsuitable for this study.

Design outcomes

Primary

Measure	Time frame
Number, function and differentiation of the immune cells such as NK, monocyte, neutrophil, dendritic cell, helper T cell, Th17, regulatory T cell, NKT cell	—

Countries

Japan

Contacts

Public ContactAkihiko Yokohama

Graduate School of Medicine, Gunma University Department of Medicine and Clinical Science

027-220-8166

Outcome results